The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline on the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer.
While SBRT is the current standard of care for peripherally located tumors in patients who cannot undergo surgery, the new guideline addresses the appropriateness of SBRT for medically inoperable patients with high-risk clinical scenarios requiring curative focused therapy, according to ASTRO. It also reviews the role of SBRT for centrally located tumors, which have unique risks compared to peripheral tumors, the society said.
The guideline is available for free in Practical Radiation Oncology, ASTRO's clinical practice journal.
